Profund Advisors LLC Reduces Holdings in Dyne Therapeutics, Inc. $DYN

Profund Advisors LLC cut its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 23.0% in the second quarter, Holdings Channel.com reports. The fund owned 23,642 shares of the company’s stock after selling 7,077 shares during the quarter. Profund Advisors LLC’s holdings in Dyne Therapeutics were worth $225,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. CWM LLC grew its holdings in shares of Dyne Therapeutics by 168.1% during the second quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after purchasing an additional 1,900 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Dyne Therapeutics by 378.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock valued at $32,000 after purchasing an additional 2,446 shares during the period. Quarry LP acquired a new stake in shares of Dyne Therapeutics in the 1st quarter valued at about $47,000. Bryce Point Capital LLC purchased a new position in Dyne Therapeutics during the 2nd quarter worth approximately $115,000. Finally, E Fund Management Co. Ltd. increased its position in Dyne Therapeutics by 16.2% during the first quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company’s stock worth $144,000 after buying an additional 1,923 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

DYN opened at $18.79 on Friday. Dyne Therapeutics, Inc. has a twelve month low of $6.36 and a twelve month high of $31.32. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -4.87 and a beta of 1.16. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The company has a fifty day simple moving average of $16.18 and a 200 day simple moving average of $13.04.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.05. Equities research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, CEO John Cox sold 2,640 shares of the business’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $13.41, for a total value of $35,402.40. Following the transaction, the chief executive officer owned 199,539 shares in the company, valued at approximately $2,675,817.99. The trade was a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 14.14% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Evercore ISI restated an “outperform” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a report on Thursday, November 6th. JPMorgan Chase & Co. dropped their price target on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, October 8th. HC Wainwright increased their price objective on shares of Dyne Therapeutics from $38.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, Oppenheimer lowered their price target on Dyne Therapeutics from $13.00 to $11.00 and set a “market perform” rating for the company in a report on Wednesday. Four research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.93.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.